source
- German biotech Immatics eyes pivotal Phase 3 readout after promising uveal melanoma cell therapy resultsImmatics, a German biotech founded 26 years ago, is focusing on cancer immunotherapy. Its lead candidate is an experimental cell therapy targeting uveal melanoma. Early Phase 1 data in 16 patients…
- Mark Cuban's Cost Plus Drugs targets rare disease market with custom n-of-1 therapiesMark Cuban's Cost Plus Drugs, known for low-cost generics, is expanding into rare disease treatments. The company has dedicated part of its new manufacturing plant to producing custom "n-of-1" the…